RECRUITING

The Effects of the CF Carrier State on the Kidneys and Pancreas

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.

Official Title

The Effects of the CF Carrier State on the Kidneys and Pancreas

Quick Facts

Study Start:2021-12-20
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05474417

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * A CF Carrier identified via genetic testing
  1. * CF patient status
  2. * Unable to speak English
  3. * Currently pregnant
  4. * Unable to provide written informed consent
  5. * Prisoner status
  6. * Currently taking any medications for the treatment of diabetes

Contacts and Locations

Study Contact

Philip M Polgreen, MD
CONTACT
(319) 384-6194
philip-polgreen@uiowa.edu
Shelby L Francis, PhD
CONTACT
319-678-8037
shelby-francis@uiowa.edu

Principal Investigator

Philip M Polgreen, MD
PRINCIPAL_INVESTIGATOR
University of Iowa

Study Locations (Sites)

University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States

Collaborators and Investigators

Sponsor: Philip Polgreen

  • Philip M Polgreen, MD, PRINCIPAL_INVESTIGATOR, University of Iowa

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-12-20
Study Completion Date2024-12

Study Record Updates

Study Start Date2021-12-20
Study Completion Date2024-12

Terms related to this study

Additional Relevant MeSH Terms

  • Carrier State
  • Pancreatic Disease
  • Kidney Diseases